10-Q: Vaxart Reports First Quarter 2024 Financial Results, Provides Pipeline Update

Vaxart's first quarter 2024 results show increased revenue from government contracts and non-cash royalties, alongside ongoing research and development expenses.

Summary

• Vaxart reported a net loss of $24.4 million for the first quarter of 2024, compared to a net loss of $25.1 million for the same period in 2023.
• The company's total revenue for the quarter was $2.18 million, a significant increase from $0.675 million in the first quarter of 2023, driven by government contract revenue and non-cash royalty revenue.
• Research and development expenses were $19.0 million, slightly down from $19.6 million in the same quarter of the previous year.
• General and administrative expenses increased to $7.2 million from $6.6 million year-over-year.
• Vaxart's cash, cash equivalents, and investments totaled $36.7 million as of March 31, 2024.
• The company raised $8.4 million through its at-the-market facility and $9.9 million through a securities purchase agreement during the quarter.
• Vaxart expects its current cash runway to extend into late fourth quarter of 2024.

Sentiment

Score: 4

Explanation: The document shows a company with promising technology but significant financial challenges. While there are positive developments in revenue and pipeline progress, the ongoing losses and need for additional funding create a cautious outlook.

Positives

• Revenue increased significantly due to government contracts and non-cash royalties.
• The company secured a $9.3 million contract with BARDA to support clinical trial planning.
• Vaxart successfully raised capital through equity offerings.
• The net loss decreased slightly compared to the same period last year.
• The company has a cash runway into late fourth quarter of 2024.

Negatives

• Vaxart continues to operate at a loss, with a net loss of $24.4 million for the quarter.
• The company's cash balance decreased from $34.7 million to $26.7 million during the quarter.
• Research and development expenses remain high at $19.0 million.
• The company is dependent on raising additional capital to fund operations.

Risks

• Vaxart's ability to continue as a going concern is dependent on raising additional capital.
• The company is subject to risks associated with clinical trials and regulatory approvals.
• The company's reliance on government funding through the BARDA contract poses a risk if funding is reduced or terminated.
• The company faces risks related to the development and commercialization of its vaccine candidates.
• There is a risk that the company may not be able to achieve marketing approval for its vaccine candidates.

Future Outlook

Vaxart expects to meet with the FDA in the middle of 2024 to discuss data on correlates of protection for its norovirus vaccine, which will inform potential next steps. The company also expects to initiate a Phase 2b clinical trial for its XBB COVID-19 vaccine candidate as early as the second quarter of 2024. Vaxart expects its current cash runway to extend into late fourth quarter of 2024.

Management Comments

• Management intends to complete additional financing transactions in the next 12 months.
• Management's plans include further reducing or delaying operating expenses if the company is unable to raise additional capital.

Industry Context

Vaxart is operating in the competitive biotechnology sector, focusing on oral vaccine development. The company's focus on oral vaccines differentiates it from many competitors who are developing injectable vaccines. The company is also working on vaccines for major infectious diseases such as COVID-19, norovirus, and influenza, which are areas of significant public health need.

Comparison to Industry Standards

• Vaxart's Q1 2024 net loss of $24.4 million is typical for a clinical-stage biotechnology company with no products on the market.
• The company's R&D expenses of $19.0 million are in line with other companies in the sector that are actively developing multiple vaccine candidates.
• The company's cash position of $36.7 million is relatively low compared to some of its peers, highlighting the need for additional funding.
• Compared to companies like Moderna and BioNTech, which have commercialized mRNA vaccines, Vaxart is still in the clinical development phase.
• Vaxart's focus on oral vaccines is a differentiator, as most vaccine companies are focused on injectable vaccines. This could provide a competitive advantage if successful.

Management Changes

Legal Proceedings

• The company is involved in ongoing legal proceedings, including a securities class action lawsuit and a lawsuit related to short-swing profits.
• The company reached a partial settlement in the securities class action lawsuit, agreeing to a settlement amount of $12.0 million, with $2.0 million to be paid by the company and the remainder by its insurers.
• A motion for summary judgment was granted in the short-swing profits lawsuit, dismissing all claims, but the plaintiff has filed a notice of appeal.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential future equity offerings.
• Employees may be impacted by potential cost-cutting measures if the company is unable to raise additional capital.
• Customers (potential future patients) may benefit from the development of new oral vaccines.
• Suppliers and creditors may be impacted by the company's financial situation and ability to meet its obligations.

Next Steps

• Vaxart plans to meet with the FDA to discuss data on correlates of protection for its norovirus vaccine.
• The company expects to initiate a Phase 2b clinical trial for its XBB COVID-19 vaccine candidate as early as the second quarter of 2024.
• Vaxart intends to complete additional financing transactions in the next 12 months.

Key Dates

Keywords

Vaxart, Vaccine Development, Oral Vaccines, Clinical Trials, Biotechnology, COVID-19 Vaccine, Norovirus Vaccine, Influenza Vaccine, BARDA, Financial Results